News

Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
Novo Nordisk’s Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...
Novo Nordisk's Wegovy weight loss drug sales soar 67% in second quarter
Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Wegovy maker Novo Nordisk to cut costs as competition grows
Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...
Devdiscourse1d
Novo Nordisk Faces Challenges as Copycat Competition Intensifies
Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...
Novo Nordisk expands legal battle over compounded weight loss drugs
Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.
Fierce Pharma4h
Novo Nordisk's US marketing head Ulrich Otte steps down
Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...